You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Spain: These 53 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Spain

Generic Entry Dates in Other Countries

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Spain: These 53 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Tradename Ingredient Estimated Entry Opportunity Date
QNASL beclomethasone dipropionate 2024-05-21
CREON pancrelipase (amylase;lipase;protease) 2025-08-15
ERIVEDGE vismodegib 2024-09-02
ESBRIET pirfenidone 2025-09-22
OLYSIO simeprevir sodium 2025-07-29
>Tradename >Ingredient >Estimated Entry Opportunity Date

Details: Spain: These 53 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

When can QNASL (beclomethasone dipropionate) generic drug versions launch?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 21, 2024
Generic Entry Controlled by: Spain Patent 2,339,574

Drug Price Trends for QNASL
QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Spain Patent 2,320,174

CREON is a drug marketed by

This drug has fifty-two patent family members in thirty-two countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Spain Patent 2,341,284

CREON is a drug marketed by

This drug has fifty-two patent family members in thirty-two countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Spain Patent 2,377,430

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ESBRIET (pirfenidone) generic drug versions launch?

Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Spain Patent 2,496,144

ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Eighteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Spain Patent 2,360,473

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Spain Patent 2,555,230

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can VICTRELIS (boceprevir) generic drug versions launch?

Generic name: boceprevir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2025
Generic Entry Controlled by: Spain Patent 2,572,980

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-three countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

When can XALKORI (crizotinib) generic drug versions launch?

Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2025
Generic Entry Controlled by: Spain Patent 2,402,419

XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-eight countries.

See drug price trends for XALKORI.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Spain Patent 2,378,778

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Spain Patent 2,535,179

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can PICATO (ingenol mebutate) generic drug versions launch?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Spain Patent 2,461,315

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-four patent family members in twenty-one countries. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.

When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?

Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Spain Patent 2,388,744

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has forty-eight patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?

Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Spain Patent 2,727,523

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has forty-eight patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?

Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Spain Patent 2,848,841

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has forty-eight patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,369,671

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,728,788

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can SUSTOL (granisetron) generic drug versions launch?

Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Spain Patent 2,529,574

SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

See drug price trends for SUSTOL.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,414,095

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,540,966

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,686,981

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?

Generic name: indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Spain Patent 2,362,429

Drug Price Trends for ARCAPTA NEOHALER
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries.

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Spain Patent 2,392,848

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Spain Patent 2,600,405

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Spain Patent 2,362,429

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,360,811

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,408,216

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,510,840

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,549,763

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Spain Patent 2,380,887

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Spain Patent 2,540,204

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Spain Patent 2,370,136

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Spain Patent 2,375,788

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can SPINRAZA (nusinersen sodium) generic drug versions launch?

Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Spain Patent 2,397,113

SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.

This drug has one hundred and one patent family members in twenty-seven countries.

See drug price trends for SPINRAZA.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.

When can SPINRAZA (nusinersen sodium) generic drug versions launch?

Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Spain Patent 2,545,223

SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.

This drug has one hundred and one patent family members in twenty-seven countries.

See drug price trends for SPINRAZA.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.

When can SPINRAZA (nusinersen sodium) generic drug versions launch?

Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Spain Patent 2,702,531

SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.

This drug has one hundred and one patent family members in twenty-seven countries.

See drug price trends for SPINRAZA.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.

When can AXUMIN (fluciclovine f-18) generic drug versions launch?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 29, 2025
Generic Entry Controlled by: Spain Patent 2,663,496

AXUMIN is a drug marketed by Blue Earth. There are seven patents protecting this drug.

This drug has twenty-nine patent family members in sixteen countries.

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

When can HALAVEN (eribulin mesylate) generic drug versions launch?

Generic name: eribulin mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 03, 2024
Generic Entry Controlled by: Spain Patent 2,748,200

HALAVEN is a drug marketed by Eisai Inc. There are two patents protecting this drug.

This drug has seventy-eight patent family members in twenty-six countries. There has been litigation on patents covering HALAVEN

See drug price trends for HALAVEN.

The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this generic product. Additional details are available on the eribulin mesylate profile page.

When can NEURACEQ (florbetaben f-18) generic drug versions launch?

Generic name: florbetaben f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 17, 2024
Generic Entry Controlled by: Spain Patent 2,526,655

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

When can VARITHENA (polidocanol) generic drug versions launch?

Generic name: polidocanol
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 21, 2025
Generic Entry Controlled by: Spain Patent 2,366,399

VARITHENA is a drug marketed by Provensis. There are four patents protecting this drug.

This drug has ninety-seven patent family members in thirty countries.

See drug price trends for VARITHENA.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this generic product. Additional details are available on the polidocanol profile page.

When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,291,780

Drug Price Trends for NUCYNTA
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,359,504

Drug Price Trends for NUCYNTA
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can OTREXUP (methotrexate) generic drug versions launch?

Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 24, 2025
Generic Entry Controlled by: Spain Patent 2,716,135

Drug Price Trends for OTREXUP
OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.

This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

When can OZEMPIC (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Spain Patent 2,350,051

Drug Price Trends for OZEMPIC
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can OZEMPIC (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Spain Patent 2,557,313

Drug Price Trends for OZEMPIC
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,414,095

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,540,966

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,686,981

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,872,962

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can NEVANAC (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 02, 2024
Generic Entry Controlled by: Spain Patent 2,348,249

Drug Price Trends for NEVANAC
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 06, 2024
Generic Entry Controlled by: Spain Patent 2,404,697

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,582,646

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,593,582

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,754,573

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can LYRICA CR (pregabalin) generic drug versions launch?

Generic name: pregabalin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2025
Generic Entry Controlled by: Spain Patent 2,449,231

Drug Price Trends for LYRICA CR
LYRICA CR is a drug marketed by Upjohn. There are three patents protecting this drug and four Paragraph IV challenges. Nine tentatively approved generics are ready to enter the market.

This drug has thirty-seven patent family members in thirty-three countries.

See drug price trends for LYRICA CR.

The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-one suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.

When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,291,780

Drug Price Trends for NUCYNTA ER
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,359,504

Drug Price Trends for NUCYNTA ER
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can TRACLEER (bosentan) generic drug versions launch?

Generic name: bosentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 17, 2025
Generic Entry Controlled by: Spain Patent 2,336,943

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

When can APTIOM (eslicarbazepine acetate) generic drug versions launch?

Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Spain Patent 2,371,556

Drug Price Trends for APTIOM
APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

When can APTIOM (eslicarbazepine acetate) generic drug versions launch?

Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Spain Patent 2,562,816

Drug Price Trends for APTIOM
APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?

Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2024
Generic Entry Controlled by: Spain Patent 2,332,009

Drug Price Trends for BELVIQ
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

When can BOSULIF (bosutinib monohydrate) generic drug versions launch?

Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 01, 2025
Generic Entry Controlled by: Spain Patent 2,449,197

BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

When can CAPRELSA (vandetanib) generic drug versions launch?

Generic name: vandetanib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 21, 2024
Generic Entry Controlled by: Spain Patent 2,330,025

CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.

This drug has forty patent family members in thirty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Spain Patent 2,313,581

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can DUEXIS (famotidine; ibuprofen) generic drug versions launch?

Generic name: famotidine; ibuprofen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 18, 2025
Generic Entry Controlled by: Spain Patent 2,380,747

Drug Price Trends for DUEXIS
DUEXIS is a drug marketed by Horizon. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS

See drug price trends for DUEXIS.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Spain Patent 2,370,136

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Spain Patent 2,375,788

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can JYNARQUE (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,358,217

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can JYNARQUE (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,379,153

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can JYNARQUE (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,527,794

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2025
Generic Entry Controlled by: Spain Patent 2,408,687

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2025
Generic Entry Controlled by: Spain Patent 2,535,478

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 20, 2024
Generic Entry Controlled by: Spain Patent 2,348,038

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can NEXAVAR (sorafenib tosylate) generic drug versions launch?

Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 07, 2025
Generic Entry Controlled by: Spain Patent 2,351,612

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,582,646

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,593,582

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,754,573

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can SAMSCA (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,358,217

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can SAMSCA (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,379,153

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can SAMSCA (tolvaptan) generic drug versions launch?

Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Spain Patent 2,527,794

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

When can TYKERB (lapatinib ditosylate) generic drug versions launch?

Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 19, 2025
Generic Entry Controlled by: Spain Patent 2,601,503

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

When can VITEKTA (elvitegravir) generic drug versions launch?

Generic name: elvitegravir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 20, 2024
Generic Entry Controlled by: Spain Patent 2,388,441

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 03, 2025
Generic Entry Controlled by: Spain Patent 2,522,895

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: Spain Patent 2,374,553

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 25, 2024
Generic Entry Controlled by: Spain Patent 2,303,255

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the rifamycin profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Spain Patent 2,308,689

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can WAKIX (pitolisant hydrochloride) generic drug versions launch?

Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 10, 2025
Generic Entry Controlled by: Spain Patent 2,309,948

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

When can VYONDYS 53 (golodirsen) generic drug versions launch?

Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,361,325

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.

This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.

When can VYONDYS 53 (golodirsen) generic drug versions launch?

Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,564,185

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.

This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.

When can VYONDYS 53 (golodirsen) generic drug versions launch?

Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Spain Patent 2,627,917

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.

This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.

When can XCOPRI (cenobamate) generic drug versions launch?

Generic name: cenobamate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 22, 2025
Generic Entry Controlled by: Spain Patent 2,441,765

Drug Price Trends for XCOPRI
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty countries.

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

When can KOSELUGO (selumetinib sulfate) generic drug versions launch?

Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2025
Generic Entry Controlled by: Spain Patent 2,421,746

KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.

This drug has one hundred and ninety-eight patent family members in forty-four countries.

See drug price trends for KOSELUGO.

The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 14, 2025
Generic Entry Controlled by: Spain Patent 2,405,611

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 14, 2025
Generic Entry Controlled by: Spain Patent 2,405,611

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and fourteen patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,437,268

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,446,324

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,567,197

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,569,357

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,667,868

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,743,531

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can WEGOVY (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Spain Patent 2,350,051

Drug Price Trends for WEGOVY
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can WEGOVY (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Spain Patent 2,557,313

Drug Price Trends for WEGOVY
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Spain Patent 2,872,962

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can ARNUITY ELLIPTA (fluticasone furoate) generic drug versions launch?

Generic name: fluticasone furoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2024
Generic Entry Controlled by: Spain Patent 2,561,421

Drug Price Trends for ARNUITY ELLIPTA
ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

This drug has one hundred and sixteen patent family members in twenty-seven countries. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.

When can RECORLEV (levoketoconazole) generic drug versions launch?

Generic name: levoketoconazole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 10, 2025
Generic Entry Controlled by: Spain Patent 2,377,526

RECORLEV is a drug marketed by Strongbridge. There are seven patents protecting this drug.

This drug has thirty-two patent family members in twenty countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,892,304

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can BAXDELA (delafloxacin meglumine) generic drug versions launch?

Generic name: delafloxacin meglumine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 08, 2024
Generic Entry Controlled by: Spain Patent 2,901,955

BAXDELA is a drug marketed by Melinta. There are thirteen patents protecting this drug.

This drug has one hundred and ten patent family members in twenty-eight countries. There has been litigation on patents covering BAXDELA

See drug price trends for BAXDELA.

The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this generic product. Additional details are available on the delafloxacin meglumine profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Spain Patent 2,906,792

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can OTREXUP (methotrexate) generic drug versions launch?

Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 24, 2025
Generic Entry Controlled by: Spain Patent 2,908,027

Drug Price Trends for OTREXUP
OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.

This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

When can ZTALMY (ganaxolone) generic drug versions launch?

Generic name: ganaxolone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2025
Generic Entry Controlled by: Spain Patent 2,812,250

ZTALMY is a drug marketed by Marinus. There are eight patents protecting this drug.

This drug has forty-two patent family members in fifteen countries.

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 15, 2025
Generic Entry Controlled by: Spain Patent 2,930,658

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 29, 2024
Generic Entry Controlled by: Spain Patent 2,290,844

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can FOLOTYN (pralatrexate) generic drug versions launch?

Generic name: pralatrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 30, 2024
Generic Entry Controlled by: Spain Patent 2,313,365

FOLOTYN is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-one patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN

See drug price trends for FOLOTYN.

The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.

When can DEFENCATH (heparin sodium; taurolidine) generic drug versions launch?

Generic name: heparin sodium; taurolidine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2024
Generic Entry Controlled by: Spain Patent 2,456,946

DEFENCATH is a drug marketed by Cormedix. There are four patents protecting this drug.

This drug has fourteen patent family members in eight countries.

The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this API. Additional details are available on the heparin sodium; taurolidine profile page.

When can DEFENCATH (heparin sodium; taurolidine) generic drug versions launch?

Generic name: heparin sodium; taurolidine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2024
Generic Entry Controlled by: Spain Patent 2,951,567

DEFENCATH is a drug marketed by Cormedix. There are four patents protecting this drug.

This drug has fourteen patent family members in eight countries.

The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this API. Additional details are available on the heparin sodium; taurolidine profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,362,282

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,535,618

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,566,363

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,585,576

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,665,287

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,938,727

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can VITEKTA (elvitegravir) generic drug versions launch?

Generic name: elvitegravir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 20, 2024
Generic Entry Controlled by: Spain Patent 2,960,824

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.